The effect of sex hormones on hemostasis and cardiovascular riskfactors in postmenopausal women
Author: Pripp, Ulla
Date: 2004-11-19
Location: Rum
Time: 9.00
Department: Institutionen för medicin / Department of Medicine
Abstract
The influence of cardiac riskfactors and sex hormones on hemostasis were
studied in healthy women (n=260) in Study I. Body mass Index (BMI),
dyslipidemia, surgical menopause, smoking and years since menopause were
associated with an increase of 28% in fibrinogen levels. BMI, total
cholesterol (tot. chol.) and Hormone Replacement Therapy (HRT) explained
an increase of 5 % on levels of factor VII activity (VIla). Triglycerides
(TG), tot. chol., BMI, years since menopause and HRT explained increases
in Factor VII antigen (VIIag) levels of 25 %. Low levels of high density
lipoprotein (HDL) and years since menopause explained an 8% increase in
von Willebrand factor antigen (vWFag) levels. BMI explained 20% and TG 3%
of the increase in plasminogen activator inhibitor 1 (PAI-1) levels.
In Study II, 21 postmenopausal women with CHD and 42 postmenopausal healthy women were studied for a possible influence of CHD on sex steroids. Estradiol-17 beta (E2) levels were significantly higher in CHD patients. Further, significantly higher ratios between serum E2 and estrone (El) and between serum 4-androstene3.17-dione (A4) and dehydroepiandrosterone (DHEA) were seen in CHD patients.
In Study III, sexual hormone binding globuline (SHBG) and corticosteroid binding protein (CBG) as markers for changes in hemostatic factors were studied in postmenopausal women with CHD on oral HRT (n=15) or placebo (n=13). A negative correlation between pretreatment values of PAI-1 and SHBG was found. Oral HRT increased levels of CBG, SHBG, and F VII and decreased levels of PAI-1 and antithrombin ( AT).
In Studies IV and V, the effects of HRT on ambulatory blood pressure (ABP), lipids, angina pectoris and quality of life were studied in 60 postmenopausal women with CHD. In Study IV, oral HRT had the most pronounced effects on ABP. A rise in both daytime and night-time systolic ABP was observed after 6 cycles. After 12 cycles, a decrease was observed in night-time ABP. Transdermal HRT did not affect ABP. A decrease in night-time systolic ABP was observed in the placebo group after 12 cycles. In the oral HRT group, moderate beneficial effects on lipids were observed after 12 cycles. The effects were less pronounced in the transdermal group. In Study V, no significant difference between the treatment groups in the occurrence of angina pectoris was observed between baseline and 6 and 12 months.
In Study III, sexual hormone binding globuline (SHBG) and corticosteroid binding protein (CBG) as markers for changes in hemostatic factors were studied in postmenopausal women with CHD on oral HRT (n=15) or placebo (n=13). A negative correlation between pretreatment values of PAI-1 and SHBG was found. Oral HRT increased levels of CBG, SHBG, and F VII and decreased levels of PAI-1 and antithrombin (AT). In Studies IV and V, the effects of HRT on ambulatory blood pressure (ABP), lipids, angina pectoris and quality of life were studied in 60 postmenopausal women with CHD. In Study IV, oral HRT had the most pronounced effects on ABP. A rise in both daytime and night-time systolic ABP was observed after 6 cycles. After 12 cycles, a decrease was observed in night-time ABP. Transdermal HRT did not affect ABP. A decrease in night-time systolic ABP was observed in the placebo group after 12 cycles. In the oral HRT group, moderate beneficial effects on lipids were observed after 12 cycles. The effects were less pronounced in the transdermal group. In Study V, no significant difference between the treatment groups in the occurrence of angina pectoris was observed between baseline and 6 and 12 months.
Conclusions: BMI, tot. chol., TG och HDL appear to affect the hemostatis more than hormonal status and age in healthy postmenopausal women. The elevated levels of E2 in postmenopausal women with CHD might reflect an increased conversion of El to E2 secondary to inflammation. The correlation found between "steroid sensitive" proteins and hemostatic factors was an increase of SHBG levels and a decrease in PAI-1 levels, which might be a beneficial effect of HRT. Oral hormone therapy has a beneficial effect on lipoprotein levels. HRT has no effect on ABP and seems not to affect symptoms of angina pectoris.
In Study II, 21 postmenopausal women with CHD and 42 postmenopausal healthy women were studied for a possible influence of CHD on sex steroids. Estradiol-17 beta (E2) levels were significantly higher in CHD patients. Further, significantly higher ratios between serum E2 and estrone (El) and between serum 4-androstene3.17-dione (A4) and dehydroepiandrosterone (DHEA) were seen in CHD patients.
In Study III, sexual hormone binding globuline (SHBG) and corticosteroid binding protein (CBG) as markers for changes in hemostatic factors were studied in postmenopausal women with CHD on oral HRT (n=15) or placebo (n=13). A negative correlation between pretreatment values of PAI-1 and SHBG was found. Oral HRT increased levels of CBG, SHBG, and F VII and decreased levels of PAI-1 and antithrombin ( AT).
In Studies IV and V, the effects of HRT on ambulatory blood pressure (ABP), lipids, angina pectoris and quality of life were studied in 60 postmenopausal women with CHD. In Study IV, oral HRT had the most pronounced effects on ABP. A rise in both daytime and night-time systolic ABP was observed after 6 cycles. After 12 cycles, a decrease was observed in night-time ABP. Transdermal HRT did not affect ABP. A decrease in night-time systolic ABP was observed in the placebo group after 12 cycles. In the oral HRT group, moderate beneficial effects on lipids were observed after 12 cycles. The effects were less pronounced in the transdermal group. In Study V, no significant difference between the treatment groups in the occurrence of angina pectoris was observed between baseline and 6 and 12 months.
In Study III, sexual hormone binding globuline (SHBG) and corticosteroid binding protein (CBG) as markers for changes in hemostatic factors were studied in postmenopausal women with CHD on oral HRT (n=15) or placebo (n=13). A negative correlation between pretreatment values of PAI-1 and SHBG was found. Oral HRT increased levels of CBG, SHBG, and F VII and decreased levels of PAI-1 and antithrombin (AT). In Studies IV and V, the effects of HRT on ambulatory blood pressure (ABP), lipids, angina pectoris and quality of life were studied in 60 postmenopausal women with CHD. In Study IV, oral HRT had the most pronounced effects on ABP. A rise in both daytime and night-time systolic ABP was observed after 6 cycles. After 12 cycles, a decrease was observed in night-time ABP. Transdermal HRT did not affect ABP. A decrease in night-time systolic ABP was observed in the placebo group after 12 cycles. In the oral HRT group, moderate beneficial effects on lipids were observed after 12 cycles. The effects were less pronounced in the transdermal group. In Study V, no significant difference between the treatment groups in the occurrence of angina pectoris was observed between baseline and 6 and 12 months.
Conclusions: BMI, tot. chol., TG och HDL appear to affect the hemostatis more than hormonal status and age in healthy postmenopausal women. The elevated levels of E2 in postmenopausal women with CHD might reflect an increased conversion of El to E2 secondary to inflammation. The correlation found between "steroid sensitive" proteins and hemostatic factors was an increase of SHBG levels and a decrease in PAI-1 levels, which might be a beneficial effect of HRT. Oral hormone therapy has a beneficial effect on lipoprotein levels. HRT has no effect on ABP and seems not to affect symptoms of angina pectoris.
List of papers:
I. Pripp U, Eriksson-Berg M, Orth-Gomer K, Schenck-Gustafsson K, Landgren BM (2004). Does body mass index, lipoprotein levels, hormone replacement therapy, surgical menopause and age affect haemostasis in postmenopausal women? J Gender Med. [Accepted]
II. Pripp U, Schenck-Gustafsson K, Soderqvist G, von Schoultz B, Landgren BM, Carlstrom K (2004). Circulating sex steroids in postmenopausal women with coronary heart disease. [Submitted]
III. Pripp U, Schenck-Gustafsson K, Landgren BM, Carlstrom K (2004). Circulating concentrations of hemostatic factors and two "sterid sensitive proteins" during oral hormone replacement therapy in women with coronary heart disease. Scand J Lab Clin Invest. [Accepted]
View record in Web of Science®
IV. Pripp U, Hall G, Csemiczky G, Eksborg S, Landgren BM, Schenck-Gustafsson K (1999). A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease. J Hypertens. 17(10): 1379-86.
Pubmed
V. Hall G, Pripp U, Schenck-Gustafsson K, Landgren BM (1998). Long-term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas. 28(3): 235-42.
Pubmed
I. Pripp U, Eriksson-Berg M, Orth-Gomer K, Schenck-Gustafsson K, Landgren BM (2004). Does body mass index, lipoprotein levels, hormone replacement therapy, surgical menopause and age affect haemostasis in postmenopausal women? J Gender Med. [Accepted]
II. Pripp U, Schenck-Gustafsson K, Soderqvist G, von Schoultz B, Landgren BM, Carlstrom K (2004). Circulating sex steroids in postmenopausal women with coronary heart disease. [Submitted]
III. Pripp U, Schenck-Gustafsson K, Landgren BM, Carlstrom K (2004). Circulating concentrations of hemostatic factors and two "sterid sensitive proteins" during oral hormone replacement therapy in women with coronary heart disease. Scand J Lab Clin Invest. [Accepted]
View record in Web of Science®
IV. Pripp U, Hall G, Csemiczky G, Eksborg S, Landgren BM, Schenck-Gustafsson K (1999). A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease. J Hypertens. 17(10): 1379-86.
Pubmed
V. Hall G, Pripp U, Schenck-Gustafsson K, Landgren BM (1998). Long-term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas. 28(3): 235-42.
Pubmed
Issue date: 2004-10-29
Publication year: 2004
ISBN: 91-7349-982-X
Statistics
Total Visits
Views | |
---|---|
The ...(legacy) | 324 |
The ... | 121 |
Total Visits Per Month
October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | April 2024 | |
---|---|---|---|---|---|---|---|
The ... | 0 | 0 | 0 | 2 | 0 | 1 | 0 |
Top country views
Views | |
---|---|
United States | 55 |
Sweden | 52 |
China | 41 |
Germany | 40 |
Russia | 11 |
South Korea | 9 |
India | 7 |
Finland | 6 |
Ireland | 6 |
France | 5 |
Top cities views
Views | |
---|---|
Kiez | 15 |
Beijing | 12 |
Seoul | 9 |
Sunnyvale | 8 |
Des Moines | 6 |
Dublin | 6 |
Bengaluru | 5 |
Kostroma | 5 |
Göteborg | 4 |
Stockholm | 4 |